Loading clinical trials...
Loading clinical trials...
An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of BRV in the conversion of partial onset seizure patients from combination treatment to monotherapy.
Age
16 - 75 years
Sex
ALL
Healthy Volunteers
No
Little Rock, Arkansas, United States
Garden Grove, California, United States
Loma Linda, California, United States
Newport Beach, California, United States
Riverside, California, United States
Sacramento, California, United States
Stanford, California, United States
Denver, Colorado, United States
Fort Collins, Colorado, United States
Danbury, Connecticut, United States
Start Date
August 1, 2008
Primary Completion Date
March 1, 2010
Completion Date
March 1, 2010
Last Updated
July 11, 2018
62
ACTUAL participants
Brivaracetam
DRUG
Brivaracetam
DRUG
Lead Sponsor
UCB Pharma
NCT06700356
NCT02531880
NCT05871372
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions